An Open-label, Multi-center Phase II Trial to Evaluate the Efficacy and Safety of Combination Chemotherapy With DoceTaxel(Detaxel) and Oxaliplatin(Oxalitin)in Recurrent or Metastatic Breast Cancer
Recent therapeutic developments, such as the introduction of new cytotoxic agents (taxanes,
platinum, liposomal anthracyclines, etc) have resulted in constant improvements in treatment
efficacy and consequently in recurrent or metastatic outcome. This single arm, multicenter
phase II study was designed to evaluate the response rate, toxicity, progression free
survival of docetaxel and oxaliplatin in patients with recurrence or metastatic breast
cancer.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
overall response rate
2 years
Yes
Sehwan Han, MD.PhD.
Principal Investigator
Department of Surgery, Breast Cancer Center,Inje University Paik Hospital, South Korea
Korea: Food and Drug Administration
KBCSG008
NCT01351597
April 2011
September 2013
Name | Location |
---|